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Abstract 
 
Transcriptional regulation contributes to the hierarchy of processes that 
ensure proteins are expressed in the correct cells at appropriate times. Such 
exquisite control is critical for neurohormones, which are induced in response 
to specific physiological signals, and for which inappropriate expression has 
pathological consequences. The basal transcription of genes is modulated by 
the sequence-specific binding of transcription factors (TFs) to enhancer or 
repressor elements within the gene control regions.  These TFs are modular 
proteins, which use specialized DNA-binding domains to interact at the correct 
DNA sequence motifs. Here they form scaffolds that recruit regulatory co-
factors to modify surrounding the chromatin. The nature of these co-factors 
determines whether a TF functions as an activator or a repressor of 
transcription (Figure 1).  Here we consider classes of TFs that regulate the 
expression of neuropeptides, drive the development of neuroendocrine 
tissues, or define neuroendocrine cancers.  Genome-wide studies are now 
beginning to reveal the extent and diversity of the binding motifs for individual 
TFs. Many TFs regulate transcription of messenger RNAs and also non-
coding RNAs, which themselves exert transcriptional or post-transcriptional 
regulation of gene expression. The regulation of TFs by alternative splicing, 
post-translational modifications, protein-protein interactions and subcellular 
re-localization also diversifies their function (Figure 1). TFs often contribute to 
cascades of transcriptional regulators, or work in feedback loops. Thus 
transcriptional regulation is complex, co-operative and dynamic, relying on the 
integration of signals generated by multiple TFs to determine the 
transcriptional output of a given gene. This chapter discusses these themes 
and some of the experimental techniques used to study the regulation and 
function of TFs, highlighting specific neuroendocrine-associated examples.  
We focus on (i) the diversity of function for REST, a TF with roles in 
neuroendocrine physiology and oncogenesis, (ii) the transcriptional cascades 
that drive development of the hypothalamic-pituitary axis, and (iii) context-
dependent TF function at the gene promoter for the neuropeptide AVP. 
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1) The key players in transcriptional regulation 
 
1.1 Core transcriptional complexes 
Mammalian transcription relies on three multi-subunit core RNA polymerases. 
RNA pol I and III regulate expression of ribosomal and transfer RNAs 
respectively.  Most pertinent here, RNA pol II regulates expression of 
messenger RNA (mRNA) coding for proteins, microRNA (miRNA) and long 
non-coding RNA (lncRNA).  The TATA binding protein (TBP) and a host of 
other general transcription factors are required to correctly position RNA pol II 
on gene promoters and to support efficient transcriptional initiation.  In 
addition, another multi-protein complex called Mediator is universally required 
to function as an adapter between these general transcription factors, RNA 
pol II, and the sequence-specific transcription factors (TFs) that ultimately 
determine transcriptional output.  
 
1.2 Sequence-specific transcription factors (TFs) 
Recent attempts to comprehensively catalog all the human or murine 
sequence-specific TFs estimate the total number at between 850 and 1900 
(Fulton et al., 2009,Vaquerizas et al., 2009). A significant proportion of these 
TFs are at present completely uncharacterized.  Many different TFs have 
been implicated in regulating the expression of neuropeptides and their 
cognate receptors, or in driving neuroendocrine development or 
carcinogenesis; some key examples are listed in Table 1.  A global survey of 
sequence-specific TF mRNA expression shows they comprise approximately 
6% of the expressed genes in all tissues, with between 150 and 300 different 
TFs expressed in any individual tissue.  These TFs fall into two general 
categories, those that are expressed ubiquitously throughout the tissues of 
the body, and those that are restricted to one or two specific tissues 
(Vaquerizas et al., 2009).  Examples of TFs involved in neuroendocrine 
processes fall into both of these expression categories (Extended Table 1).   
 
All sequence-specific TFs have two major types of domain, which act 
independently.  The first is a DNA-binding domain (DBD) that mediates direct 
binding of TFs to specific DNA regulatory elements. TFs are classified into 
more that seventy families on the basis of the specialized DBDs they utilize 
(Fulton et al., 2009,Luscombe et al., 2000).  TFs use these structured 
domains to probe the topography of the DNA double helix, most commonly 
the major groove, until they recognize the specific pattern of bases that 
represents their preferred binding motif.  Most TFs employ an a-helix within 
their DBD for this purpose, and variation in the amino acid (aa) sequence of 
the DBD generates the differential base specificity of individual TFs.  A single 
DBD element typically recognizes only a very short motif of several base pairs 
(bp) in length, which would be inadequate to provide suitable specificity within 
a mammalian genome. However, the scope of these recognition motifs is 
often extended, either by employing multimerized arrays of binding domains 
within the TF, or by dimerization between two TFs allowing them to recognize 
a longer, often inverted, repeat.   
 
Historically, the gene-by-gene empirical determination of DNA sequences 
bound by a TF was used to define their canonical binding motifs.  This 
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employed techniques such as DNA footprinting, electrophoretic mobility shift 
assay (EMSA) and reporter gene assays.  However, technological advances 
now enable us to map the binding sites for a given TF across an entire 
mammalian genome.  Methods include (i) computational predictions using 
motif searches, (ii) protein binding microarrays, and (iii) systematic evolution 
of ligands by exponential enrichment (SELEX), or (iv) chromatin 
immunoprecipitation (ChIP), followed by either microarray analysis (ChIP-
chip) or next generation sequencing (ChIP-seq).  
 
SELEX is an in vitro method used to identify the DNA sequence binding 
preferences for a TF within a pool of random oligonucleotides, whilst ChIP 
enables a snapshot of in vivo binding by cross-linking TFs at their 
physiological binding sites within the cellular chromatin environment.  High 
throughput SELEX has now defined binding motifs for over 200 human TFs; 
although the structural families of TFs as classified by their DBDs do have 
distinct binding preferences, more precise binding profiles can be used to sub-
classify families (Jolma et al., 2013). These approaches often reveal 
surprisingly wide-scale and diverse binding sites for TFs, and may uncover 
novel physiological roles through ontology and pathway profiling of the 
datasets.  There are caveats to these studies though. Firstly binding is highly 
dependent on the physiological context; computation predictions and SELEX 
cannot account for the cellular environment, whilst ChIP data is specific to the 
cell line used.  Secondly, in vivo occupancy of sites does not always equate to 
transcriptional output.  Some estimates suggest that only 25% of TF binding 
sites identified by ChIP-seq in mammalian cells are linked to transcriptional 
activity (Spitz & Furlong, 2012). Expression profiling of the TF-responsive 
transcriptome by microarray or next generation sequencing of RNA (RNA-
seq) therefore remain key to understanding the physiological relevance of TF 
binding. 
 
The major functions of a TF are often conserved across species.  However TF 
binding motifs within DNA evolve rapidly, and the overlap between the human 
and mouse genomes may be as low as 10% (Vaquerizas et al., 2009).  This 
chapter predominantly discusses TFs with human and rodent orthologs, likely 
to perform similar functions within neuroendocrine systems. However, their 
genome-wide binding profiles may vary significantly between species.  The 
DBD targets a TF in a promoter-dependent fashion.  This enables precise 
control of the expression of individual genes, as TFs have a second class of 
domain that mediates protein-protein interactions to recruit transcriptional co-
factors to the gene promoter.  Many co-factors bear functional domains that 
can enhance or repress the activity of the core transcriptional complexes 
(Figure 1).  
 
1.3 Transcriptional co-factors 
Genomic DNA is packaged by nucleosomes, composed of the core histone 
proteins H2A, H2B, H3 and H4. Less structured “tails” of each histone 
protrude from the complex, and aa-residues within the tails are targeted for 
post-translational modification (PTM). These PTMs form a complex histone 
code that alters the dynamic chromatin environment, rendering it more or less 
accessible to general and sequence-specific TFs. The code is determined by 
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many variables including the type, number and location of the PTMs, and the 
position of the nucleosome within the gene architecture (Li et al., 2007). The 
writers, readers and erasers of the histone code are transcriptional co-factors.  
Most sequence-specific TFs can interact with a wide gamut of co-factors, 
either simultaneously recruiting a large complex with multiple activities 
towards chromatin, or using alternative co-factors to provide spatial or 
temporal context to their activity. 
 
Many co-factors possess enzymatic activities that add or remove histone 
PTMs.  For example, addition of acetyl groups by histone acetyl transferases 
(HATs) opens up the chromatin structure and is associated with 
transcriptional activation, whilst their removal by histone deacetylases 
(HDACs) leads to chromatin condensation and transcriptional repression.  In 
contrast, methylation presents a more complex code: increasing methylation 
of histone H3 on lysine 4 (H3K4) is associated with transcriptional activation, 
whilst H3K9 or H3K27 methylation is repressive.  Families of methyl 
transferases and demethylases mediate these reversible modifications.  
Histone readers are recruited to the modified histone residues to act as 
scaffolds that bring in additional co-factors, ensuring an orchestrated 
progression of modifications to determine whether a gene is transcribed or 
repressed. 
 
The ATP-dependent chromatin remodeling SWI/SNF complexes also 
modulate transcription.  As nucleosome positioning influences TF occupancy 
at enhancers, nucleosome displacement may be required to expose low-
affinity TF binding sites. Components of the remodeling complexes, such as 
BRG1 or BAF, may be recruited as transcriptional co-factors by pioneer TFs, 
which prime the promoter for binding of other TFs (Spitz & Furlong, 2012).   
 
Intriguingly, some non-coding RNAs act as novel classes of transcriptional co-
factor. Mechanistically, lncRNAs may act as signals that mimic TFs, decoys 
that titrate TFs away from DNA, guides that recruit co-factors in the absence 
of TFs, or scaffolds that bring together multiple TFs and/or co-factors at 
chromatin (Wang & Chang, 2011). Small modulatory double-stranded RNAs 
(smRNAs) of around 20bp in length can also act as TF decoys by mimicking 
binding motifs, or may modulate interaction between the TF and its co-factors. 
 
 
 
2) Classes of neuroendocrine-associated TFs 
 
As summarized in Table 1, TFs that regulate the neuroendocrine phenotype 
fall into many different classes based on their DBDs.  Full names and further 
details for all of these TFs can be accessed through Extended Table 1 on the 
associated website.  Here we briefly overview selected TFs, highlighting their 
DNA binding preferences and roles in neuroendocrine physiology. 
 
2.1 Basic leucine zipper (bZIP) 
The bZIP domain forms a long continuous a-helix consisting of two functional 
halves.  The first is a basic region that makes contact with the DNA, typically 
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recognizing a short sequence of 4-bp to 5-bp.  The second mediates 
dimerization through formation of a coiled-coil structure.  Homodimerization 
dictates that the active TF recognizes an inverted repeat, but 
heterodimerization generates alternate factors that recognize distinct 
asymmetrical binding sites.  Key examples of neuroendocrine-associated 
bZIP TFs are the FOS and JUN family, which heterodimerize to constitute the 
AP1 transcription factor, and the CREB/ATF family.   
 
CREB1 binds as a homodimer to an 8-bp palindrome known as the cAMP 
response element (CRE) and is the textbook example of a TF whose activity 
is controlled by phosphorylation.  In response to cAMP signaling, protein 
kinase A (PKA) is activated, phosphorylating CREB1 on serine-133. CREB1 
then translocates into the nucleus and interacts with its co-factor CREBBP to 
activate target gene transcription. CREB1 is co-activated by a family of 
TORCs, with TORC1 and TORC2 most highly expressed in the parvocellular 
and magnocellular neuroendocrine hypothalamus. TORCs are 
phosphorylated and held in an inactivate state in the cytoplasm by 14-3-3 
proteins; when dephosphorylated they move into the nucleus to interact with 
CREB1, facilitating its interaction with the transcriptional complex. This may 
be a requirement for CREB-dependent activation, for example corticotrophin 
releasing hormone (CRH) transcription requires both phosphorylation of 
CREB1 and nuclear translocation of TORC2 (Aguilera & Liu, 2012). In 
contrast, CREB3L1 is normally sequestered in the endoplasmic reticulum 
membrane, from where it is cleaved in response to inducing stresses, allowing 
translocation into the nucleus to activate transcription.  CREB3L1 was 
recently shown to play a pivotal role in osmotic induction of arginine 
vasopressin (AVP) expression (section 4).  
 
2.2  Basic helix-loop-helix (bHLH)  
The bHLH factors also utilize a basic a-helix to contact DNA, typically binding 
a 6-bp E-box motif (CANNTG), the canonical form of which is the palindromic 
sequence CACGTG.  The bHLH factors are obligate dimers, and a flexible 
loop region connects their DNA-binding helix to a second a-helix that enables 
dimerization. Although homodimerization does occur, heterodimerization is 
more common and interaction with different dimerization partners provides 
diversity in sequence recognition and co-factor recruitment.   
 
The transcriptional activator ASCL1 has roles in neural and neuroendocrine 
progenitor development. ASCL1 is expressed at high levels in human 
neuroendocrine cancers and forced overexpression of Ascl1 is sufficient to 
drive development of neuroendocrine lung cancers in mice (Linnoila et al., 
2000).  In mouse embryonic brain (E12.5) or cultured neural stem cells, 
genome-wide ChIP-chip identified binding sites for Ascl1 in ~1200 proximal 
promoters. Enriched amongst these, were genes controlling the 
neurotransmitter biosynthetic process. Combining these data with expression 
profiling revealed transcriptional targets that both drive neuronal differentiation 
and promote cell cycle progression (Castro et al., 2011).  Like ASCL1, 
NEUROD1 and USF2 are also expressed in neuroendocrine cancers. 
Physiologically NEUROD1 is required for specification of pituitary 
corticotropes, pathologically it is implicated in a positive feedback loop in 
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small cell lung cancer (SCLC), as it is upregulated in response to nicotine and 
increases nicotinic acetylcholine receptor subunit transcription. USF1 and 
USF2 predominantly heterodimerize, but also form homodimers with distinct 
binding specificities (Rada-Iglesias et al., 2008). USF2 is overexpressed in 
SCLC and promotes proliferation (Ocejo-Garcia et al., 2005), whilst 
USF1/USF2 regulate expression of neuropeptides including AVP, calcitonin 
gene related peptide (CGRP) and preprotachykinin (PPT-A) (Coulson et al., 
1999a,Coulson et al., 2003,Paterson et al., 1995,Viney et al., 2004). 
 
A subfamily of bHLH-PAS factors combines this bHLH domain with PAS 
(Per/Arnt/Sim) domains that can bind small molecules or other proteins to 
sense and respond to environmental signals.  A heterodimer of two bHLH-
PAS factors ARNT2/SIM1 play key roles in hypothalamic development, whilst 
CLOCK/BMAL1 and HIF1A contribute to regulation of the AVP promoter 
(section 4). 
 
2.3 Forkhead (FOX) 
The forkhead or winged-helix domain is a distinct DBD of around 100-aa, and 
FOX factors bind to DNA as monomers.  The hepatic factor FOXA2 plays 
roles in developmental systems and is implicated in regulation of 
neuropeptide gene expression.  FOXA2 is a pioneer factor that opens up 
compacted chromatin to enable binding of other TFs including nuclear 
receptors (Kaestner, 2010).  It also works in a co-operative fashion with USF 
factors to activate transcription of CGRP (Viney et al., 2004). 
 
2.4 Homeoboxes 
There are more than 300 homeobox genes of different sub-classes encoded 
by the human genome, many of which are associated with developmental 
processes.  They are characterized by a helical DBD, which is essential for 
function, and are divided into further sub-classes according to their other 
protein domains. Functions of these TFs in the neuroendocrine hypothalamic-
pituitary axis are described in section 4. 
 
2.4.1 POU homeoboxes 
Fifteen homeoboxes belong to the POU (Pit1/Oct/Unc86) subclass.  They 
utilize two DBDs, an N-terminal POU-specific domain (~75-aa) that is 
separated from the C-terminal homeobox domain (~60-aa) by a non-
conserved region (5-aa to 20-aa).  Each domain uses a helix-turn-helix motif 
to contact 5-bp to 6-bp of DNA, and both are required for high affinity DNA 
binding. Many of these factors have roles in neuroendocrine systems, in 
particular the class I factor POU1F1 (PIT1) that binds the motif TAAAT, and 
the class III factor POU3F2 (BRN2) (Prince et al., 2011). 
 
2.4.2 PRD homeoboxes 
The PRD class is characterized by a serine residue at position 50 that dictates 
binding specificity and a second conserved PAX DBD.  The PRD-like factors 
have a very similar homeobox, but lack these two key features.  A number of 
PRD (e.g. PAX4, PAX6) and PRD-like factors (e.g. HESX1, OTP, PITX1, 
PITX2, PROP1) are involved in neuroendocrine development. 
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2.4.3 NKL homeoboxes  
The NKL class genes originate from the NK homeobox cluster in Drosophila 
and often contain an upstream TN motif.  HMX2, HMX3 and NKX2-1, which 
participate in hypothalamic development, serve as examples of this class. 
 
2.4.4 LIM homeoboxes 
LIM homeodomain factors contain, in addition to a central homeobox, two N-
terminal cysteine-rich LIM domains that mediate protein-protein interactions.  
Examples include LHX3 and LHX4 that participate in pituitary development. 
 
2.5 T-box (TBX) 
The TBX domain is quite large at around 20kDa and is structurally distinct 
from other DBDs. TFs of this family bind to the DNA consensus sequence 
TCACACCT.  These TFs are mainly involved in developmental processes and 
TBX19 is required for differentiation of pituitary corticotropes (section 4). 
 
2.6 High mobility group box (HMG-box) 
The HMG-box domain contains three a-helices, separated by loops, that 
make contact with DNA in the minor groove. High affinity HMG-box binding is 
restricted to unwound DNA conformations. SOX3 acts as a developmental 
switch, counteracting the activity of proneural factors to suppress neuronal 
differentiation.  It is required for formation of the hypothalamic-pituitary axis 
(section 4).  SOX10 is also associated with neuroendocrine tissues; it is 
expressed in pulmonary neuroendocrine carcinoids and is implicated in 
development of gonadotrophin releasing hormone (GnRH) cells in Zebrafish 
(Whitlock et al., 2005). 
 
2.7 Nuclear hormone receptor (NR) 
These TF sensors of steroids and other hormones typically have a C-terminal 
ligand-binding domain and an N-terminal activation domain, which is ligand-
dependent.  The central DBD is comprised of two zinc fingers (ZFs) and binds 
to the hormone response element (HRE).  NRs are held in an inactive state in 
the cytosol and, on ligand sensing, move into the nucleus and bind directly to 
DNA, either as monomers or as dimers.  For example, the glucocorticoid 
receptor NR3C1 recognizes inverted repeats of a 6-bp DNA motif that are 
separated by a 3-bp spacer. NR3C1 requires chromatin remodeling by BRG1, 
a component of the SWI/SNF complex, to access many of its binding sites.  In 
this context, FOXA2 or AP1 may act as pioneer factors to enable chromatin 
remodeling on which NR3C1 recruitment is dependent (Spitz & Furlong, 
2012).  The lncRNA GAS5 acts as a decoy for NR3C1 as its stem-loop 
structure mimics the glucocorticoid response element to which NR3C1 
normally binds (Kino et al., 2010).  NR3C1 has pervasive roles in 
neuroendocrinology and may also interact with other transcription factors, 
altering expression of their responsive genes.  Another NR factor, NR5A1 
(SF1) is required for development of the adrenal gland, gonads and pituitary 
gonadotropes. Intriguingly, NR5A1 not only binds its own canonical motif, 
CAAGGHCA, but can also occupy the RE1 motif used by the ZF repressor 
REST (Doghman et al., 2013).  
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2.8. Zinc finger (ZF) 
Zinc fingers are comprised of around 30-aa and co-ordinate a single zinc ion 
at the base of the finger through pairs of conserved cysteine and histidine 
residues.  Each ZF typically recognizes only 3-bp of DNA, and so they are 
commonly strung together in sequence to produce larger DBDs. Over 600 
human TFs use ZFs to bind DNA.  Many examples associated with 
neuroendocrine regulation primarily act as transcriptional repressors. These 
either silence neuroendocrine gene expression in non-neuroendocrine 
tissues, or promote differentiation by switching off expression of genes that 
suppress neuroendocrine gene expression.  Consideration of the preferred 
DNA binding motifs for some specific ZF factors illustrates that this prevalent 
DBD can provide diverse recognition profiles for individual TFs within the 
human genome (Figure 2).   
 
INSM1 is a ZF repressor whose expression is tightly restricted to endocrine 
tissues.  It has a C-terminal DBD comprised of five ZFs, which recognize a 
12-bp consensus motif (Figure 2).  INSM1 is transiently expressed during 
neuroendocrine differentiation and regulates development of the endocrine 
pancreas, as well as the noradrenergic sympathetic neurons and chromaffin 
cells of the sympathoadrenal gland.  INSM1 is also highly overexpressed in 
most neuroendocrine cancers (Lan & Breslin, 2009). IKZF1 was originally 
described as a lymphocyte differentiation factor, although it also influences 
hypothalamic-pituitary cell development, differentiation, proliferation and 
transformation (section 4). IKZF1 has a C-terminal interaction domain 
involved in dimerization and an N-terminal DBD comprised of five ZFs, 
although its preferential DNA recognition motif is not well established. 
Interestingly, IKZF1 exists as several alternatively spliced isoforms, most of 
which lack sufficient ZFs to bind DNA efficiently, and act in a dominant 
negative fashion.  IKZF1 isoforms are expressed in pituitary adenomas, and 
act as transcriptional activators or repressors for a variety of hormones, such 
as pro-opiomelanocortin (POMC), growth hormone, (GH), prolactin (PRL) and 
GH-releasing hormone (GHRH) (Ezzat & Asa, 2008). 
 
SCRT1 is a transcriptional repressor that utilizes five ZFs to bind DNA at E-
box motifs, competing with bHLH factors. It is a neural-specific repressor, 
expressed in newly differentiated post-mitotic neurons, and may mediate a 
switch to migratory neurons (Itoh et al., 2013). SCRT1 is expressed in 
neuroendocrine cancers, where it antagonizes the pro-neural bHLH factors 
ASCL1 and E12 (Nakakura et al., 2001). In contrast SP1 is widely expressed 
with numerous physiological roles. SP1 has three ZFs that bind GC-rich DNA 
motifs (Figure 2), and it may act as either a transcriptional repressor or 
activator. SP1 is associated with transcriptional activation of POMC and 
GnRH.  GATA2, involved in specification of pituitary gonadotropes and 
thyrotopes, is also quite widely expressed.  It possesses a different class of 
GATA-type ZF, in which four cysteine residues coordinate the zinc ion.  These 
highly conserved DBDs bind to the motif (A/T)GATA(A/G). 
 
An example of a TF that prevents neuroendocrine expression in inappropriate 
tissues is REST, also known as NRSF. The central DBD of REST consists of 
eight ZFs, which bind a 21-bp consensus RE1 motif (Figure 2).  However, as 
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discussed below, intensive study of genome-wide REST occupancy finds this 
motif to be highly divergent and surprisingly prevalent. REST is widely 
expressed outside the nervous system and was first described as a silencer of 
neuronal genes in non-neuronal cells (Chong et al., 1995,Schoenherr & 
Anderson, 1995).  However, REST is now known to dynamically regulate a 
broad spectrum of target genes and is implicated in many facets of the 
neuroendocrine phenotype (section 3). 
 
 
3) REST: a zinc finger TF with complex regulation and diverse function 
 
REST controls transcription of vast repertoire of target genes that play key 
roles in development and normal physiology. REST dysregulation is 
associated with diseases as diverse as Down’s syndrome, epilepsy, 
neurodegeneration and cancer, where it acts in a context-dependent fashion 
as either an oncoprotein or a tumor suppressor (Coulson, 2005,Negrini et al., 
2013).  Importantly, the loss of REST in neuroendocrine lung cancers licences 
inappropriate expression of neuropeptides, neurosecretory pathway 
components and neurotransmitter receptors, which can convey growth 
advantages (Coulson et al., 1999b,Coulson et al., 2000,Gurrola-Diaz et al., 
2003,Moss et al., 2009).  REST is a bipartite repressor, which recruits a 
variety of co-factors through N-terminal (RD1) and C-terminal (RD2) 
repression domains (Figure 3).  It is part of the pluripotency network in 
embryonic stem cells and decreases as progenitors differentiate along a 
neuronal program, permitting expression of neural-specific transcripts (Ballas 
et al., 2005).  However, REST also controls expression of many other protein-
coding mRNAs, as well as regulatory non-coding RNAs, which may act in 
feedback loops.  Perhaps unsurprisingly, its own expression and function is 
tightly regulated.   Here we use REST as a paradigm for the complexity of TF 
functionality (Figure 4). 
 
3.1 Transcription and alternative splicing of REST 
REST function is regulated in many ways, including through altering its 
transcription, or by alternative splicing that generates isoforms lacking key 
domains (Figure 3).  During neurogenesis, the reduction in REST is partly 
attributed to abrogation of REST transcription, and this may also be 
downregulated in SCLC by promoter methylation (Kreisler et al., 2010).  
However, alternative splicing in neurons, neuroblastoma and SCLC also alters 
REST function (Coulson et al., 2000,Palm et al., 1998,Palm et al., 1999).  A 
common splice variant retains an internal neural-specific exon and encodes a 
truncated isoform, known as REST4 or sNRSF, lacking the C-terminal 
repression domain. Intriguingly, the splicing regulator SRRM4 (nSR100), 
expressed in both neurons and SCLC, promotes inclusion of this exon and is 
itself a REST-target gene (Raj et al., 2011,Shimojo et al., 2013).  Other splice 
variants skip a domain required for nuclear translocation (Shimojo et al., 
2001), or truncate REST by using an alternative 3’ exon (Chen & Miller, 
2013).   
 
Although REST4 retains only five of the eights ZFs in the DBD, reducing its 
binding affinity, it may compete with REST at a subset of RE1 motifs. The 
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prevalence and consequences of REST isoforms remain under debate.  
However, the absence of RD2 in REST4 may mitigate repression of target 
genes.  For example, REST4 induction is seen on differentiation of human 
embryonic stem cells into neural progenitor cells where neuronal gene 
expression is activated (Ovando-Roche et al., 2014) and in epilepsy models 
REST4 induction corresponds with that of the neuropeptide PPT-A (Spencer 
et al., 2006).  Further physiological evidence comes from a rodent study into 
the effect of early life stress on subsequent chronic stress.  In this model, as 
the hypothalamic-pituitary-adrenal axis response increases, both REST4 
expression and the transcription of REST target genes are upregulated in the 
prefrontal cortex (Uchida et al., 2010).   
 
3.2 Post-translational modification, stability and cellular localization 
In common with many TFs, the functionality, localization and stability of REST 
are controlled by reversible PTMs and protein interactions. Mature REST is 
glycosylated (Lee et al., 2000,Pance et al., 2006), which although still poorly 
characterized, is associated with nuclear localization.  The targeting of REST 
to the nucleus has also been associated with the fifth ZF that is spliced out in 
some variants (Shimojo et al., 2001), or by the interacting proteins RILP 
(PRICKLE1), p150-glued (DCTN1) and huntigtin (HTT) (Shimojo & Hersh, 
2003,Shimojo, 2011).  In addition to relocalization, REST activity is also 
controlled by acute ubiquitin-mediated proteasomal degradation. 
 
REST becomes acutely phosphorylated during neural differentiation, cell 
division and adenoviral infection.  Using mass spectrometry, this has been 
mapped to two independent phosphodegrons close to the C-terminal 
repression domain.  Several candidate kinases have been suggested.  The 
Down’s syndrome-associated kinase DYRK1A, a transcriptional target of 
REST, interacts with the REST-SWI/SNF complex, potentially establishing a 
negative feedback loop (Lu et al., 2011), whilst casein kinase (CK1) 
phosphorylates REST in adult neurons (Kaneko et al., 2014). Activation of 
REST phosphodegrons triggers acute polyubiquitylation of REST by the E3 
ligase SCFβTrCP (BTRC) leading to its degradation (Guan & Ricciardi, 
2012,Guardavaccaro et al., 2008,Westbrook et al., 2008).  In the case of 
neural differentiation, REST degradation is antagonized by the deubiquitylase 
USP7 (Huang et al., 2011). Interestingly, different REST isoforms lack 
residues required for either phosphorylation or interaction with USP7 (Figure 
3).  REST protein abundance changes during the cell cycle, notably at the 
G2/M and M/G1 transitions; REST degrades as cells enter mitosis but rapidly 
recovers at mitotic exit.  We recently identified the deubiquitylase USP15 as a 
regulator of REST stability by siRNA screening.  Using mitotic and 
translational inhibitors we demonstrated that USP15 specifically promotes 
new REST synthesis (Faronato et al., 2013).  Intriguingly, USP15 expression 
is relatively low in post-mitotic neurons, but is amplified in glioblastoma 
(Eichhorn et al., 2012) where REST has oncogenic function (Kamal et al., 
2012).   
 
Another player in the regulation of REST activity is the telomere repeat protein 
TRF2.  In pluripotent cells, TRF2-REST complexes are sequestered in 
aggregated nuclear PML bodies and protected from proteasomal degradation.  
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However, during development, there is a switch in TRF2 isoforms, which now 
sequester REST in the cytoplasm, leading to derepression of target gene 
expression and promote acquisition of the neuronal phenotype.  Intriguingly, 
TRF2 also binds to the C-terminal of the REST4 isoform protecting its stability 
in neural progenitor cells (Ovando-Roche et al., 2014,Zhang et al., 
2008,Zhang et al., 2011). 
 
3.3. REST Transcriptional co-factors  
REST recruits a diverse cohort of transcriptional co-factors (Figure 3). For an 
extensive discussion of this topic and full referencing we refer the reader to 
two comprehensive reviews (Bithell, 2011,Ooi & Wood, 2007).  Here we focus 
on the emerging understanding of their co-operative functions and the 
significance of alternative REST co-factor complexes. 
 
3.3.1 Protein co-factors 
Yeast two-hybrid screening has identified two major REST co-repressor 
complexes: SIN3A/B that binds RD1 serving as a docking site for HDAC1/2 
(Grimes et al., 2000,Huang et al., 1999), and RCOR1 (coREST) that binds 
RD2 (Andres et al., 1999).  RCOR1 was subsequently shown to recruit many 
histone modifiers that contribute to the repressive chromatin environment. 
These include HDAC1/2 and BHC80, the demethylases LSD1 (H3K4me/me2) 
and KDM5C (JARID1C or SMCX, H3K4me2/me3), the methyl transferases 
EHMT2 (G9a, H3K9me2) and EZH2 a component of the polycomb repressive 
complex PRC2 (H3K9 and H3K27).  Intriguingly, whilst both RD1 and RD2 
must be retained for full repression of some target genes, a single repression 
domain is sufficient to repress others; this is important when considering the 
activity of isoforms like REST4.  Both full-length REST and RCOR1 can also 
interact with components of the ATP-dependent chromatin-remodeling 
complex, including BRG1 (SMARCA4), BAF53 (ACTL6A) and BAF170 
(SMARCC2), and with the methyl binding protein MECP2. In addition, REST 
can block the basal transcription machinery: it binds to TBP inhibiting 
formation of the pre-initiation complex and SCP1, inhibiting RNA pol II activity.  
 
It is suggested that step-wise recruitment of these co-factors coordinates 
progressive chromatin changes that ultimately switch off expression of target 
genes.  The nucleosome remodeling activity of BRG1 may be an early 
requirement, to provide better access and stabilize REST binding at RE1 
sites. Profiling of nucleosome positioning and of 38 histone modifications by 
ChIP-Seq analysis revealed the complexity of the chromatin landscape 
remodeled by REST (Zheng et al., 2009).  This study provides good evidence 
for co-ordination of histone modifications, as REST binding is often correlated 
with decreased acetylation (H3K4ac, H4K8ac) and active methylation marks 
(H3K4me3), but increased repressive methylation (H3K27me3, H3K9me2). 
However, not all co-factors are recruited to each REST locus concomitantly, 
and this may vary according to the cellular context (Greenway et al., 
2007,Hohl & Thiel, 2005).  Thus target genes may acquire different chromatin 
modifications as a consequence of REST binding.  The selective engagement 
of co-factors may be linked to the strength and dynamics of binding and 
repression, such that alternative co-factor complexes may distinguish 
between transient repression and long term silencing mechanisms. In this 
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context, MECP2 recognizes repressive methylation marks within CpG islands 
and can retain repression at promoters once REST is no longer bound (Ballas 
et al., 2005).  
 
3.3.2 Non-coding RNA co-factors 
To date, two ncRNAs have been shown to modulate transcriptional repression 
by REST through contrasting mechanisms (figure 4). HOTAIR, a lncRNA 
transcribed from within the HOXC cluster, acts as both a guide and a scaffold, 
to repress transcription of the HOXD cluster.  HOTAIR recruits PRC2/EZH2 
through binding to its 5’ sequence, and the LSD1/RCOR1/REST complex at 
its 3’ sequence; this molecular bridge co-ordinates H3K27 methylation by 
EZH2 with H3K4 demethylation by LSD1.  Interestingly, this HOTAIR-REST 
complex now uses the right-hand RE1 half-site to bind DNA, potentially 
altering its profile of target genes (Tsai et al., 2010).  In contrast, a double-
stranded smRNA found in neurons mimics the RE1 binding site for REST and 
results in transcriptional activation of REST target genes, specifying the fate 
of adult neural stem cells.  However, this smRNA does not act as a decoy, as 
ChIP analysis shows REST still binds to target gene promoters, but without 
recruitment of its usual co-repressors.  The smRNA was therefore suggested 
to switch the function of chromatin-associated REST from that of a repressor 
to a transcriptional activator (Kuwabara et al., 2004).  
 
3.4.  Diversity of transcriptional targets 
3.4.1 Genome-wide RE1 identification 
REST has proved of particular interest for genome-wide profiling, due to the 
long recognition motif for its DBD (Figure 2).  Numerous studies attempted to 
predict RE1 binding sites (reviewed in (Bithell, 2011,Ooi & Wood, 2007)). 
However, early empirical global studies revealed many more binding sites 
than expected. One used serial analysis of chromatin occupancy (SACO) in 
human lymphocytes; the other, in mouse kidney cells, was the first published 
ChIP-seq study (Johnson et al., 2007,Otto et al., 2007).  The increase in 
binding sites was partly due to the discovery that the RE1 motif functions as 
two half sites separated by a spacer, which varies in length from 2bp, found in 
the most common canonical sequence, up to at least 8bp (Figure 4).  
Intriguingly, RE1 motifs were later divided into subgroups that are human, 
primate, or mammal-specific, and a small group that are deeply conserved 
across reptiles, amphibians and fish (Johnson et al., 2009).  On comparison 
with the mouse genome, human RE1 motifs fell into three equal groups that 
either aligned to mouse RE1, or aligned with the mouse genome despite the 
lack of a murine RE1, or failed align with mouse genome at all. The most 
recent compilation across global occupancy studies, suggests up to 21,000 
REST binding sites within the human genome (Rockowitz et al., 2014).  
 
Broadly speaking, REST binding at both canonical and expanded RE1 motifs 
correlates with loss of transcription and occurrence of the expected histone 
marks (Zheng et al., 2009).  However, some studies suggest that only half of 
REST occupancy sites recruit co-factors (Yu et al., 2011).  The sequence 
context around an RE1 influences co-factor recruitment, and specific 
cofactors mark higher (SIN3A) or lower (EZH2) expressed targets (Rockowitz 
et al., 2014).  It is clear that REST occupancy is dynamic and depends on the 
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cellular context.  For example, tumor suppressors are identified as targets in 
cancer cells, but a very different profile of REST targets is seen in neurons 
compared to non-neuronal cells (Rockowitz et al., 2014).  Intriguingly, whilst a 
number of ChIP-validated occupancy sites are not RE1 (Johnson et al., 2008), 
other TFs may also compete for binding at RE1 motifs. ChIP-seq for SF1 in 
adrenocortical cells shows enriched occupancy at RE1 in addition to the SF1 
consensus site.  Indeed, SF1 could relieve REST repression of key 
steroidigenic genes (Doghman et al., 2013).  From a physiological 
perspective, genome-wide occupancy and transcription analyses concur that 
REST controls diverse processes, regulating expression of neuropeptides, 
neurotransmitter receptors, synaptic signaling and neuroendocrine secretion, 
as well as other TFs that drive neuronal and endocrine differentiation.   
 
3.4.2 Transcriptional targets: mRNAs and non-coding RNAs 
REST, via its myriad binding sites, regulates both mRNA and ncRNA 
expression. REST targets of both classes operate in feedback loops that 
influence protein expression of target genes, and directly impact on REST 
function.  The contribution of such mechanisms to REST-dependent 
expression networks is highlighted in Figure 4.   
 
Our interest in REST arose from the discovery that it was a negative regulator 
of neuropeptides including PPT-A (Quinn et al., 2002) and AVP (section 4).  
Other neuropeptides and hypophysiotropic hormones are also REST target 
genes, including CRH (Korosi et al., 2010), establishing REST as a 
neuroendocrine-associated TF.  Indeed ontology analysis from the first global 
ChIP study identified a role for REST in coordinating neuroendocrine 
pancreatic development (Johnson et al., 2007).  Recently, IL6 was found to 
induce neuroendocrine differentiation of prostate cancer cells through 
downregulating USP7 and accelerating REST turnover (Zhu et al., 2014).  
Targeted transcript analysis and DNA microarray studies of the REST-
dependent transcriptome, conducted in REST-deficient PC12 cells, on 
dominant negative REST expression in neuronal cells, or following siRNA 
depletion of REST in lung cancer cells, have all highlighted a role for REST in 
regulating the neurosecretory phenotype (D'Alessandro et al., 
2008,D'Alessandro et al., 2009,Hohl & Thiel, 2005,Moss et al., 2009,Pance et 
al., 2006).  Target genes in include many synaptic and dense core vesicle 
proteins, as well as the chromogranin and prohormone convertase families.   
 
Non-coding RNA is diverse in form and function (Chapter 4) and lncRNA and 
miRNA targets of REST were identified through genome-wide occupancy and 
microarray studies (Conaco et al., 2006,Gao et al., 2012,Ng et al., 
2012,Rockowitz et al., 2014).  Most recent data suggests REST occupancy at 
14% of currently annotated human miRNAs, with 4.2% of these differential 
expressed in neurons (Rockowitz et al., 2014). Currently, only a handful of 
these have been extensively investigated, most notably miR-9 and miR-124.  
These REST-regulated miRNAs often exert feedback on REST function by 
targeting REST expression, or its cofactors including SCP1, RCOR1, MECP2 
and EZH2, as well as switching neural progenitor BAF53a for neural BAF53b 
in the chromatin remodeling complex (Packer et al., 2008,Rockowitz et al., 
2014,Visvanathan et al., 2007,Wu & Xie, 2006,Yoo et al., 2009).  Intriguingly, 
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several mRNAs that are normally repressed by REST also feedback to 
regulate REST function, including the splicing factor SRRM4 (Raj et al, 2011) 
and the kinase DYRK1A (Lu et al, 2011).  Developmentally, miRNAs 
expressed as a consequence of REST downregulation, contribute to 
establishing neuronal phenotype.  For example, in combination with the TFs 
POU3F2 and MYTL1, miR-124 expression is sufficient to induce conversion of 
fibroblasts into neurons (Ambasudhan et al., 2011). Cross-regulation of these 
miRNAs also integrates REST into networks with other neuronal and 
neuroendocrine TFs such as POU3F2, NEUROD1 and CREB1 (Rockowitz et 
al., 2014,Wu & Xie, 2006). The context-specific studies published to date 
provide a glimpse into the extensive feedback between REST and ncRNAs 
that is proposed to govern maintenance and renewal of neuronal stem cells, 
differentiation and establishment of neural identity (Qureshi & Mehler, 2012).  
 
 
4) Cooperation of TFs in neuroendocrine phenotype and function 
 
4.1 Transcriptional networks in neuroendocrine development 
Neuronal differentiation is a highly coordinated process during which cells 
commit to a neuronal fate, acquire positional identities, exit the cell cycle, 
migrate and terminally differentiate.  Key to these processes are cascades of 
TFs that establish gene expression programs to develop, define and maintain 
the correct phenotypes.  Here we overview the TFs implicated in the 
development and physiological function of specific cells within the 
neuroendocrine hypothalamus and the anterior pituitary gland. 
 
4.1.1 Magnocellular and parvocellular neurons of the hypothalamus 
The hypothalamus sits below the thalamus and above the pituitary gland, to 
which it is connected; together they play a major role in homeostasis.  Two 
classes of hypothalamic neurons form functional nuclei. Magnocellular 
neurons originate in the paraventricular nucleus (PVN) and the supraoptic 
nucleus (SON) of the hypothalamus and extend their axons into the posterior 
pituitary.  In response to physiological stimuli, they release the neuropeptides 
oxytocin (OT) and AVP directly into the circulation.  In contrast, parvocellular 
neurons project from hypothalamic nuclei to the median eminence, where 
they secrete hypophysiotropic hormones.  From here, the hypophysial portal 
system runs down the pituitary stalk into the anterior lobe, where the 
hormones act on specialized pituitary cells. The parvocellular neurons are 
classified according to the hormones they produce: CRH and thyroid releasing 
hormone (TRH) neurons are found in the PVN; somatostatin (SS) neurons in 
the anterior periventricular (aPeV) nucleus; SS, GHRH and dopamine (DA) 
neurons in the arcuate (ARC) nucleus; GnRH neurons in the preoptic area 
(POA) and gonadotropin-inhibiting hormone (GnIH) neurons in the dorsal-
medial nucleus (DMN).  A number of TFs expressed in the developing 
hypothalamus were mapped to progressive definition of these neuroendocrine 
lineages using human disease mutations and rodent models (Figure 5).    
 
Otp is expressed from E10 in the mouse diencephalon, and by E17 is 
restricted to the regions from which the hypothalamic neuroendocrine nuclei 
originate (Simeone et al., 1994).  Otp is required at multiple stages of 
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development, from the initial proliferation and migration of progenitor cells, 
through neuroendocrine differentiation, and during hormone expression from 
established nuclei.  These pervasive and essential roles of Otp are apparent 
in knockout mice, which fail to form both the magnocellular and parvocellular 
neurons of the aPeV, ARC, PVN or SON, and lack hypothalamic expression 
of the neuropeptides CRH, TRH, AVP, OT, SS and DA (reviewed in (Del 
Giacco et al., 2008).  Sim1/Arnt2 act in parallel with Otp and, although not 
required in progenitor cells, Sim1/Arnt2 mutant mice have a reduced number 
of hypothalamic cells.  These mice fail to establish the SON, lack parvocellular 
and magnocellular neurons of the PVN, and SS neurons of the aPeV, and 
ultimately lose production of all these neuroendocrine hormones.  
Downstream of both Otp and Sim1/Arnt2 is Pou3f2 (also known as Brn2), 
which is normally expressed in the SON and much of the PVN.  Pou3f2 
knockout mice do not express CRH, OT or AVP, as they fail to establish the 
requisite neurons of the SON and PVN, although they do retain expression of 
TRH and SS (reviewed in (Prince et al., 2011,Szarek et al., 2010)). 
 
Sox3 may be required for proper development of most parvocellular neurons.  
Sox3 null mice, and human patients with SOX3-linked hypopituitarism 
disorder, have multiple pituitary hormone deficiencies (Szarek et al., 2010).  
Although this may also be linked to additional roles for Sox3 in the anterior 
pituitary itself, where it is required for development but not normal function.  
Other TFs implicated in development of specific parvocellular nuclei include 
Ascl1, Ikzf1, Nkx2.1, Hmx2/Hmx3 and Nr5a1.  Proneural Ascl1 (also know as 
Mash1) is broadly required for neurogenesis throughout the central nervous 
system, and Ascl1 null mice fail to develop the ARC and ventromedial nucleus 
(VMN) nuclei.  Ascl1 is linked to neuronal sub-type specification and, in the 
context of the hypothalamus, is required for establishment of GHRH 
expressing neurons.  Ikzf1 is also expressed in the developing GHRH 
neurons, and Ikzf1 knockout mice display severe neuroendocrine phenotypes 
including dwarfism (Ezzat & Asa, 2008).  Nkx2.1 (also known as Ttf1 or 
T/ebp) was originally described as a thyroid-specific TF, but is also expressed 
in developing lung and the presumptive hypothalamus.  Nkx2.1 mutant mice 
die at birth, exhibiting lung, thyroid and ventral hypothalamus defects, 
specifically in the ARC and VMN.   Two closely related TFs, Hmx2 and Hmx3, 
may have redundant functions in hypothalamic development.  Mice that are 
null for both Hmx2 and Hmx3 have a severe deficiency of GHRH neurons in 
the ARC, but not the VMN, and exhibit dwarfism. Lastly, Nr5a1 (also known 
as SF1) is required for development of the adrenals, gonads and pituitary 
gonatotropes.  Within the hypothalamus, Nr5a1 expression is restricted to the 
VMN, and is broadly required from the initial growth and migration of VMN 
precursors, to their terminal differentiation (Szarek et al., 2010).  
 
The downstream transcriptional pathways for many developmentally important 
TFs remain incompletely characterized.  However, these and other TFs 
directly regulate transcription of neuropeptides or hypophysiotropic hormones.  
For example, the CRH promoter is directly repressed by REST (Korosi et al., 
2010) and activated by POU3F2 and CREB1 (Aguilera & Liu, 2012), IKZF1 
induces GHRH transcription (Ezzat & Asa, 2008) and NKX2-1 is a 
transcriptional regulator of GnRH. 
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4.1.2 TFs that specify the anterior pituitary 
In contrast to the posterior pituitary, the anterior pituitary is a true gland.  Cells 
of the anterior pituitary fall into five distinct subtypes: gonadotropes that 
produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH); 
thyrotropes that produce thyroid-stimulating hormone (TSH); lactotropes that 
produce PRL; somatotropes that produce GH; and corticotropes that 
synthesize POMC which is processed into adrenocorticotropic hormone 
(ACTH).  These pituitary hormones are released under control of the 
hypothalamic parvocellular neurons, as receptors on the pituitary cell surface 
recognize the appropriate hypophysiotropic hormone, which increases or 
decreases their hormone secretion into the general circulation. Mutations in 
several TFs result in impaired pituitary function, and transgenic models have 
clarified the cascades of TFs that specify development of anterior pituitary 
cells.  Development of the human pituitary follows a similar, although not 
identical program, and disease-associated mutations in human patients 
suggest the TF ortholgs play similar roles. A simplified overview highlighting 
some key TFs in this developmental network is shown in Figure 6.  
 
The anterior pituitary is derived from Rathke’s pouch, an invagination of the 
oral ectoderm, under the control of a series of signaling pathways (reviewed in 
(de Moraes et al., 2012)).  Several homeobox TFs are required early in this 
process. Pitx1 (also called Tpit) and Pitx2 are expressed in Rathke’s pouch 
and persist in the gonadotropes and thyrotropes of the adult pituitary.  Lhx3, 
and the related Lhx4, are key regulators of anterior pituitary cell commitment 
and differentiation, being required for early development of Rathke’s pouch.  
Experiments in knockout mice show that pituitary expression of Lhx3 is 
dependent on both Pitx1 and Pitx2. Lhx3 also persists in the adult pituitary, 
where it directly activates transcription of various pituitary hormones and other 
regulatory TFs. 
 
HesX1 is present before Rathke’s pouch forms and its downregulation is 
required for anterior pituitary cell differentiation. HesX1 negatively regulates 
pituitary-specific Prop1, first expressed at E10.5.  Prop1 mutation is 
responsible for the hypoplastic pituitary phenotype of the Ames dwarf mouse, 
which lacks expression of GH, TSH, PRL, LH and FSH.  Prop1 regulates 
downstream expression of another pituitary-specific TF, Pou1f1 (Pit1), which 
is expressed in mice from E13.5 through to adulthood.  Pou1f1 specifies 
thyrotropes, lactotropes and somatotropes, all of which are lacking in dwarf 
mice with Pouf1 mutation.  It regulates transcription of many genes within 
these lineages, including GH, PRL and TSHb; human patients with POU1F1 
mutations are deficient in these same neurohormones (Prince et al., 2011). 
Additional TFs including Nr5a1, Gata2, Izkf1, Tbx19 and NeuroD1 are 
required later in differentiation to specify hormone-secretory pituitary cell 
types (Figure 6).  For example, Ikzf1 expression is important for anterior 
pituitary cell growth, differentiation and survival.  Ikzf1 directly regulates 
POMC expression in co-operation with PitX1 by recruiting the co-activator 
SRC/P160, and increases PRL but decreases GH expression (Ezzat & Asa, 
2008). Whilst POMC processing relies on a number of convertases, including 
PCSK1, which is transcriptionally repressed by REST (Moss et al., 2009). 
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4.2 Context-dependent regulation of the AVP promoter  
To conclude this chapter, we will briefly consider the context-dependent 
expression of the neuropeptide AVP.  In a normal physiological context, AVP 
is transcribed in and released from magnocellular neurons of the SON and 
PVN in response to changes in osmolality, and acts on AVP receptors in the 
kidneys and blood vessels to maintain homeostasis.  AVP is also transcribed 
in the suprachiasmatic nucleus (SCN) in response to circadian cues.  
However the AVP gene was first cloned and sequenced from a SCLC cell line 
(Sausville et al., 1985) and is commonly overexpressed in these 
neuroendocrine tumors, where it and can lead to the syndrome of 
inappropriate secretion of anti-diuretic hormone (SIADH) and dilutional 
hyponatraemia (Johnson et al., 1997). 
 
A decade ago, we reviewed the binding motifs and TFs that regulated 
pathological expression of the AVP gene promoter in SCLC, highlighting roles 
for loss of repression by REST through an RE1 motif at the transcriptional 
start site, and activation by USF1/USF2 through proximal E-box motifs 
(Coulson, 2002).  Interestingly, whilst USF1/USF2 bind the major E-box of the 
AVP promoter in SCLC, the bHLH-PAS heterodimer CLOCK/BMAL1 (Jin et 
al., 1999) utilizes this same E-box during circadian regulation of AVP 
transcription in the SCN.  Another bHLH-PAS factor, HIF1A, mediates 
crosstalk between hypoxic and circadian signaling by promoting BMAL1 
recruitment (Ghorbel et al., 2003).  Although the physiological transcription of 
AVP in the magnocellular neurons is induced by hyperosmotic stress and 
cAMP signaling, until recently it remained unclear which TFs mediated this 
response.  New studies found no direct role for CREB1, but instead show a 
key role for CREB3L1.  Both transcriptional induction and cellular 
relocalization of CREB3L1 are seen in response to osmotic challenge, and 
CREB3L1 can bind and activate the AVP promoter (Greenwood et al., 2014).  
The TFs that have been physically mapped to the AVP promoter are 
summarized in Figure 7. 
 
 
5) Perspectives 
 
The complex networks that regulate transcription of physiological processes 
are slowly being uncovered.  Systems biology approaches are required to 
understand how these transcriptional networks are integrated, but we do not 
yet know the full complement of TFs encoded by the human or murine 
genomes.  Study of even a single TF reveals unexpected complexity, with 
multiple levels of regulation that contribute to contextual differences in their 
transcriptional activity. Considerable advances in the techniques available to 
study TFs are enabling their roles to be established in different tissues, 
through development, and in response to specific stimuli.  Genome-wide 
maps of TF occupancy are helping to build networks, but this is hampered by 
the inter-species evolution of binding sites, and the incomplete correlation of 
binding with TF activity.  Given these limitations, mapping transcriptional 
regulation of the neuroendocrine phenotype remains a work in progress. 
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7) Glossary 
 
Histone: A small highly conserved basic protein, found in the chromatin of all 
eukaryotic cells.  
Nucleosome: The basic unit of chromatin that contains 147-bp of DNA 
wrapped around a histone octamer. 
Chromatin: The genomic DNA, histone proteins and other closely-associated 
non-histone proteins. 
ATP-dependent chromatin remodeler: Large multi-subunit molecular 
machine that uses ATP energy to reorganize nucleosome structures, often by 
sliding the nucleosome to a new position on the DNA. 
Gene promoter: the region of a gene, usually immediately 5’ to the 
transcriptional start site, which recruits multiple transcription factors. 
Enhancer element: a region of the gene that binds activating transcription 
factors. 
Silencer element: a region of the gene that binds repressing transcription 
factors. 
Pioneer factors: proteins that can penetrate condensed chromatin to pioneer 
recruitment of secondary co-factors that remodel the chromatin to allow other 
TFs access. 
Post-translational modification: the additional of a small molecule or 
peptide onto a protein after its translation is complete; modifications are 
usually reversible and regulatory. 
Gene Ontology: A universal classification system of gene functions and other 
attributes that uses a controlled vocabulary. 
Ortholog: Loci in two species that are derived from a common ancestral 
locus by a speciation event.  
Transcriptome: the full complement of transcripts produced in the cell or 
tissue under investigation. 
Microarray: The use of high-throughput hybridization technology for 
transcriptomic profiling. 
RNA-seq: The use of high-throughput sequencing techniques for 
transcriptomic profiling. 
DNA Footprinting: A technique to detect protein–DNA interactions using an 
enzyme to cut DNA, followed by analysis of the resulting cleavage pattern to 
identify the footprint that the protein protects. 
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EMSA: A technique that uses native gel electrophoresis to determine 
whether, and how specifically, a protein of interest can bind a given DNA 
sequence. 
SELEX: A combinatorial technique for producing DNAs that bind specifically 
and with high affinity to a DNA-binding protein of interest. 
ChIP-chip: Combines chromatin immunoprecipitation (ChIP) with microarray 
(chip); a high-throughput method for genome-wide identification of DNA 
regions that are bound in vivo by a target protein of interest. 
ChIP-seq: Similar to ChIP–chip, but interacting DNA motifs are read out by 
high-throughput parallel sequencing. 
 
 
 
 
 
8) Figure Legends and Tables 
 
Figure 1. Key concepts: generalized pathway by which sequence-
specific transcription factors direct physiological processes. 
The expression, cellular localization and activity of transcription factors (TFs) 
are tightly controlled. When in an active state, TFs are targeted to bind certain 
gene promoters through recognition of specific DNA motifs. TFs recruit a 
variety of co-factor complexes, which alter the chromatin environment around 
the target gene to activate or repress basal transcription.  TFs direct 
expression of both messenger RNAs (mRNA) that encode proteins and non-
coding RNAs (ncRNAs) that modulate protein expression through different 
mechanisms.  Integration of signals at a promoter determines whether the 
target gene is expressed, and this feeds into larger expression networks. 
 
Figure 2. Examples of binding motifs for neuroendocrine-associated 
zinc finger TFs. 
The position weight matrices derived by ChIP-seq (JASPAR, 
http://jaspar.genereg.net) are shown for three TFs that use DNA binding 
domains with different configurations of zinc fingers to determine their binding 
specificities: REST (8 ZF), INSM1 (5 ZF) and SP1 (3 ZF).  
 
Figure 3.  REST isoforms and co-factors. 
The major REST isoforms has two repression domains RD1 and RD2 that 
recruit differential transcriptional co-factor complexes.  Alternative splicing 
potentially generates multiple REST isoforms lacking key domains, which may 
antagonize REST function.  Examples shown are numbered according to 
Uniprot (http://www.uniprot.org/uniprot/Q13127).  Truncated isoforms are 
generated by inclusion of a neural-specific exon between exons 3 and 4 
(isoforms 2 and 3) or the use of an alternative 3’ exon 5 (Chen & Miller, 2013), 
these lack several ZFs of the DBD, RD2 and the phosphodegron. ZF5 of the 
DBD domain, which recruits USP7 and mediates nuclear localization, is 
deleted in isoforms 2 and 4. 
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Figure 4. REST as a paradigm for diversity and feedback in transcription 
factor regulation and function. 
REST binds to a diverse array of RE1 motifs and recruits co-repressors 
(green) to switch off transcription.  In the absence of REST, transcription is 
enabled that promotes the neuronal/neuroendocrine phenotype.  Target 
mRNAs include regulatory proteins (orange) and miRNAs (blue) that establish 
feedback loops with REST.  Other TFs (purple) may compete for RE1, and 
ncRNAs modulate REST interactions with the RE1 and protein co-factors. 
Grey lines show protein interactions and blue lines show ncRNA interactions. 
 
Figure 5. TFs required for development of the neuroendocrine 
hypothalamus.  
Examples of TFs that promote early commitment and later differentiation of 
the hypothalamic magnocellular and parvocellular neurons.  
 
Figure 6. TF cascades in anterior pituitary development. 
Examples of TFs that promote early commitment and later differentiation of 
anterior pituitary cells.  
 
Figure 7. Context-dependent TF regulation of the AVP promoter. 
Examples of TFs that activate or repress transcription through the AVP 
proximal promoter in response to osmotic, circadian or pathological cues. 
 
Table 1. Examples of sequence-specific transcription factors associated 
with regulation of neuroendocrine phenotype. 
HGNC human names are listed, with common names in brackets.   
See associated website for extended table with further details and external 
links. 
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TF name: 
HUMAN / Mouse 
Alternative names  DBD Type Tissue expression profiles External 
Databases 
ATF1 
Atf1 
Activating transcription factor 1, 
TREB36  
bZIP Smooth muscle, whole blood, IJV 
(1). EMBL Atlas 
Genecards 
AnimalTFBD  
CREB1 
Creb1 
cAMP responsive element 
binding protein 1, CREB 
bZIP Appendix, testis, whole blood, IJV 
(1). EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
CREB3L1 
Creb3l1 
cAMP responsive element 
binding protein 3 -like protein, 
OASIS 
bZIP General (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
FOS 
Fos 
FBJ murine osteosarcoma viral 
oncogene homolog, AP-1, C-
FOS 
bZIP Bone marrow, lung, thyroid, 
trachea (1). Stress-inducible. 
EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
JUN 
Jun 
Jun proto-oncogene, AP1, C-
JUN 
bZIP Lung, pancreas, prostate, thyroid, 
uterus (1). EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
NR3C1 
Nr3c1 
Nuclear Receptor Subfamily 3, 
Group C, Member 1, 
Glucocorticoid receptor, GR 
Nuclear 
receptor 
Smooth muscle, whole blood, JJV 
(1). EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
NR5A1 
Nr5a1 
Steridogenic factor 1, SF1, 
FT2F1 
Nuclear 
receptor 
Sex differentiation, pituitary 
gonadotrope and hypothalamic 
VMN development. 	EMBL Atlas Genecards AnimalTFDB TFe 
LHX3 
Lhx3 
LIM Homeobox 3, CPHD3, LIM3 LIM  
homeobox 
Pituitary (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
LHX4 
Lhx4 
LIM Homeobox 4, CPHD4 LIM  
homeobox 
EMBL Atlas Genecards 
AnimalTFDB 
TFe 
	 2	
HMX2 
Hmx2 
H6 family homeobox 1, NKX5-2 NKL 
homeobox 
GnRH neurons. EMBL Atlas Genecards 
AnimalTFDB 
TFe 
HMX3 
Hmx3 
H6 family homeobox 1, NKX5-1 NKL 
homeobox 
GnRH neurons. Genecards 
AnimalTFDB  
 
NKX2-1 
Nkx2.1 
NK2 homeobox 1, TTF1, TEBP NKL 
homeobox 
Fetal & adult thyroid & lung (1). 
Hypothalamic development 
(ARC, VMN). EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
POU1F1 
Pou1f1 
POU class 1 homeobox 1, PIT1 POU-I 
homeobox 
Pituitary (1). EMBL Atlas 
 
Genecards 
AnimalTFDB 
TFe 
POU3F2 
Pou3f2 
POU class 3 homeobox 2, 
BRN2, OCT7 
POU-III 
homeobox 
General (1).  Neuronal 
differentiation. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
HESX1 
Hesx1 
HESX homeobox 1, ANF PRD 
homeobox 
EMBL Atlas Genecards 
AnimalTFDB 
TFe 
OTP 
Otp 
Orthopedia homeobox PRD 
homeobox 
Hypothalamus: essential for 
development.  Neuroendocrine 
cancers. EMBL Atlas 
Genecards 
AnimalTFDB  
PAX4 
Pax4 
Paired box 4, KPD PRD 
homeobox 
Pancreatic islet development and 
insulin secretion, diurnally 
expressed in pineal gland to 
antagonize PAX6. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
PAX6 
Pax6 
Paired box 6, AN2 PRD 
homeobox 
Developing hypothalamus GnRH. 
EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
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PITX1 
Pitx1 
Paired-like homeodomain 1, 
BFT 
PRD 
homeobox 
Pituitary, tongue (1).	EMBL Atlas Genecards 
AnimalTFDB 
TFe 
PITX2 
Pitx2 
Paired-like homeodomain 1, 
RIEG1, RGS 
PRD 
homeobox 
General (1). EMBL Atlas Genecards 
AnimalTFDB 
 
PROP1 
Prop1 
Prophet of Pit1, CPHD2 
 
PRD 
homeobox 
EMBL Atlas Genecards 
AnimalTFDB 
TFe 
GATA2 
Gata2 
GATA binding protein 2, NFE1B Zinc Finger Placenta, prostate (1).	EMBL 
Atlas 
Genecards 
AnimalTFDB 
TFe 
IKZF1 
Ikzf1 
Ikaros 1, IK1, ZNFN1A1 Zinc Finger General (1). Fetal and adult 
hemo-lymphopoietic system, 
anterior pituitary, hypothalamic 
neurons. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
INSM1 
Insm1 
Insulinoma associated 1, IA-1 Zinc Finger Fetal brain, pituitary (1).  
Developing endocrine tissues, 
neuroendocrine tumors. EMBL 
Atlas 
Genecards 
AnimalTFDB 
TFe 
 
REST 
Rest 
RE-1 silencing transcription 
factor, Neural-restrictive 
silencing factor, NRSF, XBR 
Zinc Finger General (1). Neuronal progenitors 
and non-neuronal cells. Reduced 
expression or truncated variants 
in neurons and neuroendocrine 
cells. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
SCRT1 
Scrt1 
Scratch 1, ZNF898 Zinc Finger Neuronal differentiation, 
neuroendocrine cells of lung and 
lung cancers. EMBL Atlas 
Genecards 
AnimalTFDB  
TFe 
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SP1 
Sp1 
Specificity protein 1, TSFP1 Zinc Finger EMBL Atlas Genecards 
AnimalTFDB 
TFe 
FOXA2 
Foxa2 
Forkhead box A2, HNF3B Forkhead Embryonic development, 
establishment of tissue-specific 
gene expression and regulation 
of gene expression in 
differentiated tissues. 
Neuroendocrine tumors including 
prostate cancer. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
 
SOX3 
Sox3 
SRY-box 3, PHP, MRGH HMG box Required during formation of 
hypothalamic-pituitary axis. 
EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
SOX10 
Sox10 
SRY-box 10, PCWH, WS4 HMG box Salivary gland, spinal cord, 
trachea, whole brain (1). Neural 
crest and peripheral nervous 
system development. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
ASCL1 
Ascl1 
Achaete-scute complex homolg 
1, HASH1, MASH1 
bHLH Fetal brain, spinal cord, thymus, 
whole blood (1). Neuronal 
commitment, hypothalamic 
neuroendocrine differentiation, 
generation of olfactory and 
autonomic neurons. EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
NEUROD1 
Neurod1 
Neurogenic differentiation 1, 
BETA2, bHLHA3 
bHLH Differentiation: early retinal 
ganglion, inner ear sensory 
neurons, granule cells in 
hippocampus, endocrine 
pancreas, enteroendocrine small 
Genecards 
AnimalTFDB 
TFe  
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intestine, anterior pituitary 
corticotrophs. Neuroendocrine 
tumors. EMBL Atlas 
USF1 
Usf1 
Upstream transcription factor 1, 
bHLHb11, HYPLIP1, FCHL, 
MLTF 
bHLH General. EMBL Atlas Genecards 
AnimalTFDB 
TFe 
USF2 
Usf2 
Upstream transcription factor 2, 
c-fos interacting, bHLHB12, FIP 
bHLH General (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
ARNT2 
Arnt2 
Aryl hydrocarbon receptor 
nuclear translocator 2, bHLHE1 
bHLH-PAS Fetal brain, spinal cord, whole 
brain (1).  Essential 
hypothalamus development. 
EMBL Atlas 
Genecards 
AnimalTFDB 
TFe 
ARNTL 
Arntl 
Aryl hydrocarbon receptor 
nuclear translocator like,  
BMAL1, MOP3  
bHLH-PAS General (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
CLOCK 
Clock 
Clock circadian regulator, 
bHLHE8, KAT13D 
bHLH-PAS General (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
HIF1A 
Hif1a 
Hypoxia inducible factor alpha 
subunit, bHLHE78, MOP1 
bHLH-PAS Smooth muscle (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
SIM1 
Sim1 
Single minded homolog 1, 
bHLHE14 
bHLH-PAS Essential hypothalamus 
development. EMBL Atlas 
Genecards 
AnimalTFDB  
TBX19 
Tbx19 
T-box protein 19, TBS, TPIT 
 
T-box Pituitary (1). EMBL Atlas Genecards 
AnimalTFDB 
TFe 
	 6	
 
Extended Table 1.  Examples of sequence-specific transcription factors associated with regulation of neuroendocrine 
phenotype.   
Links are provided to the pages for each transcription factor at: Genecards (repository of data for human gene and protein with links 
to many other databases), Animal TFBD (human or mouse database of transcription factor data) and Transcription Factor 
Encyclopedia (TFe, minireviews of human or mouse TFs that are currently in progress).  Tissue distribution data is taken from (1) 
Vaquerizas et al. 2009, or the general literature, with links provided to the relevant EMBL Expression Atlas page. 
1. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, 
expression and evolution. Nature reviews Genetics. 2009;10:252-63. 
 
 







Zinc	  ﬁnger	  
GATA2	  
IKZF1	  
INSM1	  
REST	  
SCRT1	  
SP1	  
Basic	  leucine	  zipper	  
ATF1	  
CREB1	  (CREB)	  
CREB3L	  
FOS	  
JUN	  
Homeobox	  
LIM	  
LHX3	  
LHX4	  
NKL	  
HMX2	  
HMX3	  
NKX2-­‐1	  (TTF1)	  
POU	  	  
POU1F1	  (PIT1)	  
POU3F2	  (BRN2)	  
PRD	  
HESX1	  
OTP	  
PAX4	  
PAX6	  
PITX1	  	  
PITX2	  
PROP1	  
bHLH	  
ASCL1	  (HASH1)	  
NEUROD1	  
USF1	  
USF2	  
bHLH-­‐PAS	  
ARNT2	  
CLOCK	  
HIF1A	  
SIM1	  
Nuclear	  receptor	  
NR3C1	  (GR)	  
NR5A1	  (SF1)	  
HMG-­‐box	  
SOX3	  
SOX10	  
Forkhead	  
FOXA2	  
T-­‐box	  
TBX19	  (TPIT)	  
Table	  1.	  Examples	  of	  sequence-­‐speciﬁc	  
transcrip9on	  factors	  associated	  with	  
regula9on	  of	  neuroendocrine	  phenotype.	  	  	  
